Cancer patients with insulin-treated diabetes have four times higher mortality

March 13, 2014

People who have diabetes at the time they are diagnosed with cancer are more likely to die early than those without diabetes, concludes research published in Diabetologia (the journal of the European Association for the Study of Diabetes). The research is by Kristina Ranc, University of Copenhagen and Steno Diabetes Center, Gentofte, Denmark, and colleagues. The researchers conclude that patients with both diabetes and cancer constitute a particularly vulnerable group, and efforts are needed to reduce cancer-related mortality among these patients.

While the research base on the links between and continues to grow, little previous research has addressed the relation to different diabetes treatment types, and findings differ among different studies, including on the link between diabetes duration and mortality of relative to the non-diabetic cancer population.

"In this study, we aimed to explore differences in survival among cancer patients with diabetes prior to compared with cancer patients without diabetes," says Ranc. "A specific aim was to examine the association between different types of glucose-lowering therapies and survival after cancer diagnosis, as well as to examine how this association varies with duration of diabetes and by time since diagnosis of cancer."

This register-based study included all cancer patients diagnosed in Denmark during 1995–2009. The patients were classified into four groups according to diabetes status at the time of cancer diagnosis: no diabetes, diabetes without medication, diabetes with only oral hypoglycaemic agents (OHAs) or diabetes with insulin treatment. Since the study is entirely observational, the authors stress that causality cannot be inferred.

The researchers found that for patients with 2 years of diabetes duration and treated with insulin at the time of cancer diagnosis have 4 times higher mortality one year after cancer diagnosis. The figure is slightly different between men (3.7) and women (4.4), and there is a small increase by time since cancer diagnosis, to a 5 times increased mortality at 5 years since cancer diagnosis.

For people with diabetes using only oral antidiabetic drugs (for example, metformin), the increased risk of death was much lower, at 10% for both men and women one year after cancer diagnosis having had diabetes for two years versus non-diabetics. After 5 years, this increased risk was 50% for both men and women. For those who were not on any form of diabetes treatment, the increased risk of death was very similar to those for patients on oral antidiabetic drugs.

"The results suggest that mortality of cancer patients with pre-existing diabetes is higher relative to non-diabetic patients for all cancers combined and for most individual cancer sites," says Ranc. "In general, the highest mortality was found for insulin-treated patients, suggesting that cancer patients with more intensive diabetes treatment have a larger degree of comorbidity at the time of cancer diagnosis, and hence poorer survival. Diabetes duration at cancer diagnosis did not influence the prognosis."

The authors discuss that differences in cancer treatment between patients with and without diabetes may contribute to increased cancer-related mortality. Patients with diabetes often have other diabetes-related comorbid conditions, such as ischaemic heart disease, chronic kidney disease and neuropathy, that may influence clinical decisions.

Statistically significant increases in mortality were observed among all three groups of patients with diabetes for all cancers combined, and for colorectal, breast, ovary, cervix and corpus uteri, and bladder cancer. In addition, patients treated with insulin had a significant mortality increase for all previously mentioned cancers, as well as for rectum, lung and prostate cancer.

Referring to other research, the authors also discuss that it is possible patients with both diabetes and cancer could be less aggressively treated than non-diabetics with cancer have higher cancer-operation mortality, and that people with diabetes could present with cancer at a more advanced stage of the condition, due to diabetes masking their symptoms.

Ranc concludes: "Our study provides strong support for the notion that pre-existing diabetes increases mortality among cancer patients, and that the excess is larger among patients with diabetes treated with OHAs or, particularly, insulin...it is crucial that cancer patients with diabetes receive optimal diabetes treatment as well as any cancer-specific therapy; a therapeutic challenge requiring close collaboration between oncologists and endocrinologists."

Explore further: Cancer prevalence higher with long duration of diabetes

Related Stories

Cancer prevalence higher with long duration of diabetes

January 24, 2013
(HealthDay)—Patients diagnosed with type 2 diabetes have a greater prevalence of cancer with longer diabetes duration and with insulin use, according to a study published online Jan. 8 in Diabetes Care.

Group of anti-diabetic drugs can significantly lower cancer risk in women with type 2 diabetes

December 6, 2013
A Cleveland Clinic-led study shows that a specific type of diabetes drug can decrease the risk of cancer in female patients with type 2 diabetes by up to 32 percent.

Diabetes linked to lung cancer in postmenopausal women

May 30, 2012
(HealthDay) -- Postmenopausal women with diabetes are at a significantly higher risk of developing lung cancer, particularly if they require insulin therapy, according to research published online May 22 in Diabetes Care.

Post-breast cancer, metformin has no effect on mortality

July 3, 2013
(HealthDay)—For older women with diabetes and breast cancer, there is no association between metformin use and all-cause or breast cancer-specific mortality, according to a study published online April 30 in Diabetes Care.

Cumulative metformin linked to mortality post-prostate cancer

August 8, 2013
(HealthDay)—Among elderly men with diabetes, increased cumulative duration of metformin following a prostate cancer (PC) diagnosis correlates with decreased all-cause and PC-specific mortality, according to a study published ...

Popular diabetes drug does not improve survival rates after cancer

May 9, 2013
Despite previous scientific studies that suggest diabetes drug metformin has anti-cancer properties, a new, first-of-its-kind study from Women's College Hospital has found the drug may not actually improve survival rates ...

Recommended for you

Scientists discover a new way to treat type 2 diabetes

July 21, 2017
Medication currently being used to treat obesity is also proving to have significant health benefits for patients with type 2 diabetes. A new study published today in Molecular Metabolism explains how this therapeutic benefit ...

Alzheimer's drug cuts hallmark inflammation related to metabolic syndrome by 25 percent

July 20, 2017
An existing Alzheimer's medication slashes inflammation and insulin resistance in patients with metabolic syndrome, a potential therapeutic intervention for a highly dangerous condition affecting 30 percent of adults in the ...

Diabetes or its precursor affects 100 million Americans

July 19, 2017
Almost one-third of the US population—100 million people—either has diabetes or its precursor condition, known as pre-diabetes, said a government report Tuesday.

One virus may protect against type 1 diabetes, others may increase risk

July 11, 2017
Doctors can't predict who will develop type 1 diabetes, a chronic autoimmune disease in which the immune system destroys the cells needed to control blood-sugar levels, requiring daily insulin injections and continual monitoring.

Diabetes complications are a risk factor for repeat hospitalizations, study shows

July 7, 2017
For patients with diabetes, one reason for hospitalization and unplanned hospital readmission is severe dysglycemia (uncontrolled hyperglycemia - high blood sugar, or hypoglycemia - low blood sugar), says new research published ...

Researchers identify promising target to protect bone in patients with diabetes

July 7, 2017
Utilizing metabolomics research techniques, NYU Dentistry researchers investigated the underlying biochemical activity and signaling within the bone marrow of hyperglycemic mice with hopes of reducing fracture risks of diabetics

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.